• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

阿法替尼治疗纳武利尤单抗治疗后进展的鳞状肺癌。

Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab.

机构信息

Department of Oncology, The Second Affiliated Hospital, Harbin Medical University, Harbin, China.

出版信息

Thorac Cancer. 2018 Jan;9(1):164-166. doi: 10.1111/1759-7714.12522. Epub 2017 Oct 13.

DOI:10.1111/1759-7714.12522
PMID:29027754
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5754313/
Abstract

Nivolumab prolonged disease control in a patient with advanced squamous lung cancer that was refractory to multiple treatments. The rapid eradication of cancer after the administration of nivolumab caused hemoptysis and repeated infection. Six months after immunotherapy, mediastinal lymph node metastasis developed and afatinib effectively relieved dysphonia associated with nerve paralysis.

摘要

纳武利尤单抗使一位对多种治疗方法均无效的晚期鳞状肺癌患者的疾病得到了长时间的控制。纳武利尤单抗给药后，癌症迅速被清除，导致患者出现咯血和反复感染。免疫治疗 6 个月后，患者出现纵隔淋巴结转移，阿法替尼有效地缓解了与神经麻痹相关的声音嘶哑。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9948/5754313/025abfd1bdba/TCA-9-164-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9948/5754313/025abfd1bdba/TCA-9-164-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9948/5754313/025abfd1bdba/TCA-9-164-g001.jpg

相似文献

1
Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab.阿法替尼治疗纳武利尤单抗治疗后进展的鳞状肺癌。
Thorac Cancer. 2018 Jan;9(1):164-166. doi: 10.1111/1759-7714.12522. Epub 2017 Oct 13.
2
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.阿法替尼对比厄洛替尼二线治疗晚期肺鳞癌患者（LUX-Lung 8）：一项开放标签、随机对照、III 期临床研究。
Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5.
3
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.纳武单抗（一种抗程序性死亡蛋白1免疫检查点抑制剂）用于晚期难治性鳞状非小细胞肺癌患者的活性和安全性（CheckMate 063）：一项2期单臂试验
Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9. Epub 2015 Feb 20.
4
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.纳武单抗与多西他赛治疗晚期鳞状细胞非小细胞肺癌的疗效比较
N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.
5
Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.纳武利尤单抗在既往治疗的鳞状或非鳞状非小细胞肺癌中的疗效和安全性的暴露-反应分析。
Clin Cancer Res. 2017 Sep 15;23(18):5394-5405. doi: 10.1158/1078-0432.CCR-16-2842.
6
[Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].[阿法替尼用于肺鳞状细胞癌患者：当前情况及口服治疗选择]
Med Clin (Barc). 2016 Apr;146 Suppl 1:25-9. doi: 10.1016/S0025-7753(16)30260-3.
7
The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer.纳武单抗治疗晚期（转移性）非小细胞肺癌的安全性和疗效。
Expert Rev Anticancer Ther. 2016 Sep;16(9):903-10. doi: 10.1080/14737140.2016.1220836. Epub 2016 Aug 22.
8
Best practice in the treatment of advanced squamous cell lung cancer.晚期肺鳞状细胞癌的最佳治疗实践。
Ther Adv Respir Dis. 2015 Oct;9(5):224-35. doi: 10.1177/1753465815581147. Epub 2015 Apr 22.
9
Understanding immunotherapy for the treatment of non-small cell lung cancer.了解用于治疗非小细胞肺癌的免疫疗法。
Br J Nurs. 2016 Sep 8;25(16):S12-7. doi: 10.12968/bjon.2016.25.S12.
10
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.美国食品药品监督管理局批准摘要：纳武单抗用于治疗在铂类化疗期间或之后病情进展的转移性非小细胞肺癌。
Oncologist. 2016 May;21(5):634-42. doi: 10.1634/theoncologist.2015-0507. Epub 2016 Mar 16.

引用本文的文献

1
Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib.晚期肺鳞状细胞癌：当前的治疗方法及阿法替尼的作用
Onco Targets Ther. 2020 Sep 22;13:9305-9321. doi: 10.2147/OTT.S250446. eCollection 2020.

本文引用的文献

1
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.纳武利尤单抗单药用于晚期非小细胞肺癌的一线治疗
J Clin Oncol. 2016 Sep 1;34(25):2980-7. doi: 10.1200/JCO.2016.66.9929. Epub 2016 Jun 27.
2
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.阿法替尼对比厄洛替尼二线治疗晚期肺鳞癌患者（LUX-Lung 8）：一项开放标签、随机对照、III 期临床研究。
Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5.
3
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
纳武单抗与多西他赛治疗晚期鳞状细胞非小细胞肺癌的疗效比较
N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.